Where others have failed will Atl1102 succeed ?, page-678

@waynesworld

Both Pfizer and Sarepta are starting to perform "sub group analysis" - that old trick!

This is because Gene Therapy has shown no "overall" efficacy.

So, they are now concentrating on narrow age group cohorts who will benefit.
(Sarepta including only 4-6 year old boys).

To quote experts:

"Simply having a birthday could be the difference between a drug being recommended as helpful, or discouraged as harmful."

The FDA will not buy this!

PPMD will not buy this.

The Biotech investors are not buying it either....

So here we are, with Roche wanting ROI on their $1.3B investment, Sarepta are about to roll out Plan B.

Is it ANP or Capricor?

Capricor would be more of the same same...cell therapy!

ANP on the other hand offers access to 100% of the population - and efficacy.

Not long to find out.
.